This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Duh MS, Dial E, Choueiri TK, Fournier A-A, Antras L, Rodermund D, Neary MP, Oh WK.Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. Current Medical Research and Opinion 25: 2081-2090, No. 8, Aug 2009
Rights and permissions
About this article
Cite this article
Angiogenesis inhibitors: oral medications may save costs. Pharmacoecon. Outcomes News 588, 8 (2009). https://doi.org/10.2165/00151234-200905880-00018
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200905880-00018